AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Phio Pharmaceuticals Corp... (PHIO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

2.48

0.46 (22.77%)

At close: Jan 28, 2025, 1:54 PM

undefined% (undefined)

Bid	2.48
Market Cap	11.85M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-9.75
PE Ratio (ttm)	-0.25
Forward PE	n/a
Analyst	Buy

Ask	2.49
Volume	5,869,927
Avg. Volume (20D)	6,371,096
Open	2.21
Previous Close	2.02
Day's Range	2.00 - 2.56
52-Week Range	1.53 - 10.35
Beta	undefined

About PHIO

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic pr...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 10, 2012

Employees 8

Stock Exchange NASDAQ

Ticker Symbol PHIO

Website https://www.phiopharma.com

Analyst Forecast

According to 1 analyst ratings, the average rating for PHIO stock is "Buy." The 12-month stock price forecast is $36, which is an increase of 1351.67% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 week ago

-25.7%

Phio Pharmaceuticals shares are trading lower afte... Unlock content with Pro Subscription

1 week ago

-45.76%

Phio Pharmaceuticals shares are trading lower after the company announced a $3.19 million registered direct offering.

News

5 days ago · newsfilecorp.com

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Registration Link for Presentation and live Q&A to take place, Wednesday January 29, 2025 at 2:00 pm EST Marlborough, Massachusetts--(Newsfile Corp. - January 22, 2025) - Phio Pharmaceuticals Corp. (N...

6 days ago · newsfilecorp.com

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Raised approximately $12.08 million in gross proceeds since beginning of December 2024 Proceeds intended to be directed for development costs to be incurred in connection with PH-762 clinical activiti...

1 week ago · newsfilecorp.com

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - January 16, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA ...

1 week ago · newsfilecorp.com

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - January 15, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA ...

1 week ago · newsfilecorp.com

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - January 14, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA ...

2 weeks ago · benzinga.com

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

On Monday, Phio Pharmaceuticals Corp. PHIO stock skyrocketed with a strong session volume of 201.04 million, compared to the average volume of 362.72k, according to data from Benzinga Pro.

2 weeks ago · newsfilecorp.com

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Pathologic Complete Response reported for 2 patients with cutaneous Squamous Cell Carcinoma Marlborough, Massachusetts--(Newsfile Corp. - January 13, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) ...

3 weeks ago · newsfilecorp.com

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

INTASYL Compound RXI-231: a promising approach to treatment of hyperpigmentation Marlborough, Massachusetts--(Newsfile Corp. - January 2, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinica...

1 month ago · newsfilecorp.com

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA...

1 month ago · newsfilecorp.com

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA...

1 month ago · newsfilecorp.com

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Phio's Lead Compound PH-762 demonstrates encouraging safety profile in 2nd cohort with recommendation to escalate to next dose concentration Marlborough, Massachusetts--(Newsfile Corp. - December 19, ...

1 month ago · newsfilecorp.com

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Journal is the official publication of the International Union of Immunological Societies Marlborough, Massachusetts--(Newsfile Corp. - December 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) i...

1 month ago · newsfilecorp.com

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Award is being presented during Advanced Therapies Week 2025 in Dallas Marlborough, Massachusetts--(Newsfile Corp. - December 10, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO),) is a clinical-stag...

2 months ago · newsfilecorp.com

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

--Six sites across the U.S. are now engaged in Phase1b study Marlborough, Massachusetts--(Newsfile Corp. - November 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnolog...

2 months ago · newsfilecorp.com

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Marlborough, Massachusetts--(Newsfile Corp. - November 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company exploring new pathways towards a cancer-free futu...

2 months ago · newsfilecorp.com

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Presenting new clinical data from Phio's on-going Phase 1b trial Marlborough, Massachusetts--(Newsfile Corp. - November 7, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotech...